Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.11.25.398859: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Finally, dose-response screening enables assessment of how partial inhibition of essential activities might impact viral infection, which is a significant limitation of most genetic screening studies (Birsoy et al., 2015; Shalem et al., 2014). Our results indicate that the hit compounds identified via screening against a minimally …
SciScore for 10.1101/2020.11.25.398859: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Finally, dose-response screening enables assessment of how partial inhibition of essential activities might impact viral infection, which is a significant limitation of most genetic screening studies (Birsoy et al., 2015; Shalem et al., 2014). Our results indicate that the hit compounds identified via screening against a minimally pathogenic BSL2 coronavirus can identify compounds that inhibit the more pathogenic SARS-CoV-2 virus, a BSL3 agent. This has significant implications for antiviral development more broadly. Specifically, high-throughput screening at BSL3 or BSL4 conditions is a major impediment to the ability to conduct antiviral screening and thus represents a major barrier to the development of antiviral compounds that could block the most pathogenic viruses. The ability to screen against related BSL2 agents to identify promising compounds could spur the development of compounds against extremely pathogenic agents that require the strictest biocontainment levels. Many pharmacological screens for SARS-CoV-2 inhibitors have been performed in Vero cells (Bojkova et al., 2020; Gordon et al., 2020), which are monkey kidney cells. Vero cells have many benefits as they are easy to culture, grow quickly, and grow SARS-CoV-2 to high titers, which has been an issue for many human cell lines due to the lack of expression of the SARS-CoV-2 receptor, ACE2. However, screening for antiviral compounds in Vero cells also has limitations. They are derived from an African green monk...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
